Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis.

[1]  P. Rossing,et al.  Calcium antagonists and the diabetic hypertensive patient. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  U. Helmchen,et al.  Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. , 1992, Hypertension.

[3]  el Nahas Am,et al.  Growth factors and glomerular sclerosis. , 1992 .

[4]  M. Epstein.  Calcium antagonists and the kidney: implications for renal protection. , 1992, Kidney international. Supplement.

[5]  R. Abbate,et al.  In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. , 1991, Thrombosis research.

[6]  E. Cagliero,et al.  Pathobiology of Endothelial and Other Vascular Cells in Diabetes Mellitus: Call for Data , 1991, Diabetes.

[7]  S. Anderson.  Renal Hemodynamic Effects of Calcium Antagonists in Rats With Reduced Renal Mass , 1991, Hypertension.

[8]  P Théroux,et al.  A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. , 1990, Circulation.

[9]  L. Dworkin,et al.  Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. , 1990, The American journal of physiology.

[10]  G. Remuzzi,et al.  Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? , 1990, Kidney international.

[11]  L. Dworkin.  Effects of calcium channel blockers on experimental glomerular injury. , 1990, Journal of the American Society of Nephrology : JASN.

[12]  J. Deckers,et al.  Retardation of angiographic progression of coronary artery disease by nifedipine , 1990, The Lancet.

[13]  G. Schmitz,et al.  [The effect of Ca++ antagonists on cellular lipid metabolism]. , 1990, Arzneimittel-Forschung.

[14]  P. Shultz,et al.  Inhibition of Human Mesangial Cell Proliferation by Calcium Channel Blockers , 1990, Hypertension.

[15]  M. Mihatsch,et al.  Long-term enalapril and verapamil in rats with reduced renal mass. , 1989, Kidney international.

[16]  L. Fine,et al.  Physiology and cell biology update: polypeptide growth factors and their relation to renal disease. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[18]  A. Fogo,et al.  Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. , 1989, Kidney international.

[19]  S. Klahr,et al.  Progression of renal disease. , 1988, Seminars in nephrology.

[20]  M. Karnovsky,et al.  Focal and segmental glomerulosclerosis: analogies to atherosclerosis. , 1988, Kidney international.

[21]  P. D. Henry.  Calcium Antagonists as Antiatherogenic Agents , 1988, Annals of the New York Academy of Sciences.

[22]  R. Palmiter,et al.  Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. , 1988, The American journal of pathology.

[23]  J. Olson,et al.  Nonimmunologic mechanisms of glomerular injury. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[24]  F. Gries,et al.  Influence of a single dose of nitrendipine on whole blood platelet activity in healthy subjects. , 1988, Journal of cardiovascular pharmacology.

[25]  B. Kasiske,et al.  Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. , 1988, American journal of nephrology.

[26]  M. J. Mitchinson,et al.  MACROPHAGES AND ATHEROGENESIS , 1987, The Lancet.

[27]  D. Blache,et al.  The effect of calcium channel blockers on blood platelet function, especially calcium uptake. , 1987, Biochimica et biophysica acta.

[28]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[29]  M. Frey,et al.  Future directions in the use of calcium antagonists. , 1987, The American journal of cardiology.

[30]  D. B. Weinstein,et al.  Antiatherogenic properties of calcium antagonists. , 1987, The American journal of cardiology.

[31]  Sterzel Rb,et al.  Effects of nitrendipine on the course of experimental immunologic glomerulonephritis. , 1987 .

[32]  D. Harris,et al.  Verapamil protects against progression of experimental chronic renal failure. , 1987, Kidney international.

[33]  H. Goor,et al.  Glomerular sclerotic lesions in the rat , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.

[34]  G Poste,et al.  Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. , 1985, Cellular immunology.

[35]  M. Goligorsky,et al.  Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil. , 1985, Kidney international.

[36]  D. Hajjar,et al.  Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect. , 1985, The Journal of clinical investigation.

[37]  E. Leitersdorf,et al.  Verapamil Enhances Receptor‐Mediated Endocytosis of Low Density Lipoproteins by Aortic Cells in Culture , 1985, Arteriosclerosis.

[38]  H. Heinle,et al.  Inhibition by verapamil of the medium change induced stimulation of cultured vascular smooth muscle cells. , 1985, Arzneimittel-Forschung.

[39]  S. Klahr,et al.  Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Cameron.  Platelets in glomerular disease. , 1984, Annual review of medicine.

[41]  J. Benveniste,et al.  Effect of the Ca2+ antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and beta-glucuronidase from human neutrophils. , 1983, European journal of pharmacology.

[42]  A. Águas,et al.  Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone (DOC). , 1983, The American journal of pathology.

[43]  B. Brenner,et al.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. , 1982, The New England journal of medicine.

[44]  D. Baldwin.  Chronic glomerulonephritis: nonimmunologic mechanisms of progressive glomerular damage. , 1982, Kidney international.

[45]  R. Ross,et al.  The pathogenesis of atherosclerosis (second of two parts). , 1976, The New England journal of medicine.

[46]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.